Gene: ERBB4

2066
ALS19|HER4|p180erbB4
erb-b2 receptor tyrosine kinase 4
protein-coding
2q34
Ensembl:ENSG00000178568 MIM:600543 Vega:OTTHUMG00000133012 UniprotKB:Q15303
NG_011805.1
PubMed|SNP Mapped
4   ANCO-SNPs
ND|AD
11   
NA (AD)  NA (ND)   (Frontal_Cortex)
2.682e-1 (AD)  5.827e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs6711080chr2:212452605 (GRCh38.p7)C>Tnicotine dependenceSNV(Single Nucleotide Variation)
rs6435678chr2:211845743 (GRCh38.p7)G>Cnicotine dependenceSNV(Single Nucleotide Variation)
rs11885579chr2:211566804 (GRCh38.p7)A>Galcohol dependenceSNV(Single Nucleotide Variation)
rs13421680chr2:211551304 (GRCh38.p7)A>Galcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
SLC6A10.856
LYPD60.85
KIT0.829
C1orf210.827
ACSL60.813
TMEM132B0.802
HAPLN10.789
ARX0.787
PBX10.785
ASTN10.782

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
SFN-0.515
ANGPT2-0.502
SPINK8-0.495
GNG8-0.485
SPOCD1-0.478
ADM-0.476
TNFRSF12A-0.476
PLEKHA4-0.472
TIMP1-0.47
STC1-0.469

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB08916AfatinibSmall Molecule850140-72-6ApprovedTarget
DB12267BrigatinibSmall Molecule1197953-54-0Approved|InvestigationalTarget
ID Drug Name Action PubMed
C07699627-hydroxycholesterol27-hydroxycholesterol results in decreased expression of ERBB4 mRNA17872378
C5830744,4'-hexafluorisopropylidene diphenol"4,4'-hexafluorisopropylidene diphenol results in increased expression of ERBB4 mRNA"27567155
C0275764-hydroxy-2-nonenal4-hydroxy-2-nonenal results in decreased expression of ERBB4 mRNA12419474
C1078756-(methylamino)pyrido(3,4-d)pyrimidine"6-(methylamino)pyrido(3,4-d)pyrimidine results in decreased activity of ERBB4 protein"15572027
C496492abrineabrine results in decreased expression of ERBB4 mRNA22595364
D000082AcetaminophenAcetaminophen affects the expression of ERBB4 mRNA17562736
D000082AcetaminophenAcetaminophen affects the expression of ERBB4 mRNA25607892
D000082Acetaminophen[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB4 mRNA25607892
D000082Acetaminophen[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of ERBB4 mRNA25607892
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of ERBB4 mRNA22100608
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of ERBB4 gene27153756
D000517alpha-Chlorohydrinalpha-Chlorohydrin results in decreased expression of ERBB4 mRNA28522335
D000726Androgen Antagonists[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB4 mRNA25607892
D000726Androgen Antagonists[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of ERBB4 mRNA25607892
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of ERBB4 mRNA24449571
D001151ArsenicArsenic affects the expression of ERBB4 protein24675094
D001151ArsenicArsenic affects the methylation of ERBB4 gene25304211
C006632arsenic trioxidearsenic trioxide results in increased expression of ERBB4 mRNA19769630|2045855
D001280AtrazineAtrazine affects the expression of ERBB4 mRNA25929836
C547126AZM551248AZM551248 results in decreased expression of ERBB4 mRNA22323515
C080985batimastatbatimastat inhibits the reaction [pervanadate results in increased cleavage of ERBB4 protein]9685416
D004958EstradiolERBB4 protein promotes the reaction [Estradiol results in increased expression of PGR mRNA]20550710
D004958Estradiol[Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of ERBB4 mRNA19619570
D004958EstradiolEstradiol results in decreased expression of ERBB4 mRNA17872378|1961957
D004958EstradiolRaloxifene Hydrochloride inhibits the reaction [Estradiol results in decreased expression of ERBB4 mRNA]21185374
C070515bisindolylmaleimide Ibisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate results in increased cleavage of ERBB4 protein]9685416
C006780bisphenol A[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of ERBB4 mRNA25607892
C006780bisphenol A[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB4 mRNA25607892
C006780bisphenol A[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of ERBB4 mRNA25607892
C006780bisphenol A[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of ERBB4 mRNA25607892
C006780bisphenol Abisphenol A results in decreased expression of ERBB4 mRNA25181051
C006780bisphenol Abisphenol A results in increased expression of ERBB4 mRNA29097150
C006780bisphenol Abisphenol A results in increased methylation of ERBB4 gene28505145
D020122tert-Butylhydroperoxidetert-Butylhydroperoxide results in decreased expression of ERBB4 mRNA12419474
C038091butylparaben[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of ERBB4 mRNA25607892
C038091butylparaben[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB4 mRNA25607892
C038091butylparaben[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of ERBB4 mRNA25607892
C038091butylparaben[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of ERBB4 mRNA25607892
D003024ClozapineClozapine results in increased expression of and results in increased phosphorylation of ERBB4 protein26961615
D019327Copper SulfateCopper Sulfate results in decreased expression of ERBB4 mRNA19549813
D003375Coumestrol[Coumestrol co-treated with resveratrol] results in decreased expression of ERBB4 mRNA19167446
D003520CyclophosphamideERBB4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]16896004
D013759DronabinolDronabinol results in decreased expression of ERBB4 mRNA16616335
D003907DexamethasoneDexamethasone results in increased expression of ERBB4 mRNA16144937
D003993Dibutyl PhthalateDibutyl Phthalate results in increased expression of ERBB4 mRNA17361019
D003993Dibutyl Phthalate[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB4 mRNA25607892
D003993Dibutyl Phthalate[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB4 mRNA25607892
D003633Dichlorodiphenyl Dichloroethylene[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB4 mRNA25607892
D003633Dichlorodiphenyl Dichloroethylene[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB4 mRNA25607892
D004051Diethylhexyl Phthalate[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB4 mRNA25607892
D004051Diethylhexyl Phthalate[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB4 mRNA25607892
D004317DoxorubicinERBB4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]16896004
C038939enzacamene[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of ERBB4 mRNA25607892
C038939enzacamene[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB4 mRNA25607892
C038939enzacamene[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of ERBB4 mRNA25607892
C038939enzacamene[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of ERBB4 mRNA25607892
C109476epoxiconazole[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB4 mRNA25607892
C109476epoxiconazole[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB4 mRNA25607892
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of ERBB4 mRNA29097150
D005047EtoposideEtoposide results in decreased expression of ERBB4 mRNA15228094
D005472FluorouracilERBB4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]16896004
C412815GW 4064GW 4064 results in decreased expression of ERBB4 mRNA26655953
D006220HaloperidolHaloperidol results in increased expression of and results in increased phosphorylation of ERBB4 protein26961615
D006220HaloperidolHaloperidol results in increased expression of ERBB4 protein18184445
D007052IbuprofenIbuprofen affects the cleavage of ERBB4 protein12777371
C051890irinotecanirinotecan metabolite results in increased expression of ERBB4 mRNA15956246
C051890irinotecanirinotecan results in increased expression of ERBB4 mRNA15956246
D007649KetamineKetamine results in decreased expression of ERBB4 mRNA20000043
D008044Linuron[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB4 mRNA25607892
D008044Linuron[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB4 mRNA25607892
D008070LipopolysaccharidesERBB4 protein affects the reaction [Lipopolysaccharides results in decreased expression of SFTPB mRNA]21724861
D008070LipopolysaccharidesERBB4 protein affects the reaction [Lipopolysaccharides results in decreased expression of SFTPC mRNA]21724861
D008070LipopolysaccharidesERBB4 protein affects the reaction [Lipopolysaccharides results in increased expression of SFTPA1 mRNA]21724861
D008070LipopolysaccharidesERBB4 protein affects the reaction [Lipopolysaccharides results in increased expression of SFTPA1 protein]21724861
D008070LipopolysaccharidesERBB4 protein affects the reaction [Lipopolysaccharides results in increased expression of SFTPB protein]21724861
D008070LipopolysaccharidesERBB4 protein affects the reaction [Lipopolysaccharides results in increased expression of SFTPC protein]21724861
D008070LipopolysaccharidesERBB4 protein affects the reaction [Lipopolysaccharides results in increased expression of SFTPD mRNA]21724861
D008070Lipopolysaccharides[Lipopolysaccharides co-treated with ERBB4] affects the expression of TNF protein21724861
D058185Magnetite Nanoparticles[Succimer co-treated with Magnetite Nanoparticles] results in increased expression of ERBB4 mRNA26378955
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of ERBB4 mRNA28001369
D008769MethylnitronitrosoguanidineMethylnitronitrosoguanidine results in increased expression of ERBB4 mRNA12634122
D008825MiconazoleMiconazole results in increased expression of ERBB4 mRNA22262564
C016599mono-(2-ethylhexyl)phthalatemono-(2-ethylhexyl)phthalate results in increased expression of ERBB4 mRNA22401849
C406082monomethylarsonous acid[monomethylarsonous acid affects the acetylation of HIST3H3 protein] which affects the methylation of ERBB4 promoter18448484
D009151Mustard GasIL10 protein affects the reaction [Mustard Gas affects the expression of ERBB4 mRNA]16173061
D009532NickelNickel results in decreased expression of ERBB4 mRNA24768652|2558310
C025589ochratoxin Aochratoxin A results in decreased expression of ERBB4 mRNA22124623
C118580octylmethoxycinnamate[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of ERBB4 mRNA25607892
C118580octylmethoxycinnamate[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB4 mRNA25607892
C118580octylmethoxycinnamate[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of ERBB4 mRNA25607892
C118580octylmethoxycinnamate[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of ERBB4 mRNA25607892
C029341oxophenylarsineoxophenylarsine results in increased cleavage of and results in increased phosphorylation of ERBB4 protein9685416
D017239PaclitaxelERBB4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]16896004
D010269ParaquatParaquat results in increased expression of ERBB4 mRNA22563483
C076715pervanadatebatimastat inhibits the reaction [pervanadate results in increased cleavage of ERBB4 protein]9685416
C076715pervanadatepervanadate results in increased cleavage of ERBB4 protein9685416
C076715pervanadatepyrrolidine dithiocarbamic acid inhibits the reaction [pervanadate results in increased cleavage of ERBB4 protein]9685416
C076715pervanadatepervanadate results in increased cleavage of and results in increased activity of ERBB4 protein9685416
C076715pervanadatepervanadate results in increased cleavage of ERBB4 protein9685416
C076715pervanadatepyrrolidine dithiocarbamic acid inhibits the reaction [pervanadate results in increased cleavage of ERBB4 protein]9685416
C545373ponatinibponatinib results in decreased activity of ERBB4 protein19878872
C045362prochloraz[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB4 mRNA25607892
C045362prochloraz[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB4 mRNA25607892
C035988procymidone[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB4 mRNA25607892
C035988procymidone[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB4 mRNA25607892
D011374ProgesteroneProgesterone results in decreased expression of ERBB4 mRNA22238285
D011441PropylthiouracilPropylthiouracil results in increased expression of ERBB4 mRNA24780913
C020972pyrrolidine dithiocarbamic acidpyrrolidine dithiocarbamic acid inhibits the reaction [pervanadate results in increased cleavage of ERBB4 protein]9685416
C020972pyrrolidine dithiocarbamic acidpyrrolidine dithiocarbamic acid inhibits the reaction [pervanadate results in increased cleavage of ERBB4 protein]9685416
D020849Raloxifene HydrochlorideRaloxifene Hydrochloride inhibits the reaction [Estradiol results in decreased expression of ERBB4 mRNA]21185374
C059514resveratrol[Coumestrol co-treated with resveratrol] results in decreased expression of ERBB4 mRNA19167446
D018967RisperidoneRisperidone results in increased expression of and results in increased phosphorylation of ERBB4 protein26961615
C017947sodium arsenite[sodium arsenite affects the acetylation of HIST3H3 protein] which affects the methylation of ERBB4 promoter18448484
D004113Succimer[Succimer co-treated with Magnetite Nanoparticles] results in increased expression of ERBB4 mRNA26378955
C025462sulindac sulfidesulindac sulfide affects the cleavage of ERBB4 protein12777371
D013749Tetrachlorodibenzodioxin[Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of ERBB4 mRNA19619570
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of ERBB4 mRNA19619570
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of ERBB4 mRNA26377647
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of ERBB4 mRNA21889950
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of ERBB4 mRNA26290441
D013755Tetradecanoylphorbol Acetatebisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate results in increased cleavage of ERBB4 protein]9685416
D013755Tetradecanoylphorbol AcetateTetradecanoylphorbol Acetate results in increased cleavage of ERBB4 protein9685416
D014212TretinoinTretinoin results in decreased expression of ERBB4 mRNA23724009
D014212TretinoinTretinoin results in increased expression of ERBB4 mRNA21934132
C012589trichostatin Atrichostatin A results in decreased expression of ERBB4 mRNA24935251
D014635Valproic AcidValproic Acid results in decreased expression of ERBB4 mRNA26272509
D014635Valproic AcidValproic Acid results in increased expression of ERBB4 mRNA23179753|2438349
C025643vinclozolin[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB4 mRNA25607892
C025643vinclozolin[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB4 mRNA25607892
C025643vinclozolinvinclozolin results in increased expression of ERBB4 mRNA23555832
C111237vorinostatvorinostat results in decreased expression of ERBB4 mRNA27188386

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004709MAP kinase kinase kinase activity-IBA21873635  
GO:0004713protein tyrosine kinase activity-IBA21873635  
GO:0004713protein tyrosine kinase activity-IDA18334220  
GO:0004713protein tyrosine kinase activity-TAS-  
GO:0004714transmembrane receptor protein tyrosine kinase activity-IBA21873635  
GO:0004714transmembrane receptor protein tyrosine kinase activity-IDA18334220  
GO:0004888transmembrane signaling receptor activity-IBA21873635  
GO:0005088Ras guanyl-nucleotide exchange factor activity-TAS-  
GO:0005154epidermal growth factor receptor binding-IBA21873635  
GO:0005154epidermal growth factor receptor binding-IPI8617750  
GO:0005515protein binding-IPI9419975  10572067  10725395  11867753  16273093  16729043  
16767099  17360433  18334649  19561640  20227043  20858735  
21203579  22939624  24557338  24658140  25283809  
GO:0005524ATP binding-IEA-  
GO:0031434mitogen-activated protein kinase kinase binding-IBA21873635  
GO:0042803protein homodimerization activity-IPI18334220  
GO:0044212transcription regulatory region DNA binding-IMP15534001  
GO:0046934phosphatidylinositol-4,5-bisphosphate 3-kinase activity-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000165MAPK cascade-TAS-  
GO:0001755neural crest cell migration-ISS-  
GO:0001934positive regulation of protein phosphorylation-TAS15534001  
GO:0006351transcription, DNA-templated-IEA-  
GO:0007165signal transduction-IDA10572067  
GO:0007169transmembrane receptor protein tyrosine kinase signaling pathway-IDA10353604  18334220  
GO:0007275multicellular organism development-IBA21873635  
GO:0007399nervous system development-ISS-  
GO:0007507heart development-ISS-  
GO:0007595lactation-IMP15534001  
GO:0008283cell proliferation-TAS8383326  
GO:0008284positive regulation of cell proliferation-IMP8617750  9135143  
GO:0008285negative regulation of cell proliferation-IMP17120616  
GO:0009880embryonic pattern specification-ISS-  
GO:0009968negative regulation of signal transduction-IBA21873635  
GO:0014068positive regulation of phosphatidylinositol 3-kinase signaling-IEA-  
GO:0016477cell migration-IDA9135143  
GO:0018108peptidyl-tyrosine phosphorylation-IDA18334220  
GO:0021551central nervous system morphogenesis-ISS-  
GO:0021889olfactory bulb interneuron differentiation-ISS-  
GO:0030154cell differentiation-IBA21873635  
GO:0030334regulation of cell migration-ISS-  
GO:0033674positive regulation of kinase activity-IBA21873635  
GO:0038083peptidyl-tyrosine autophosphorylation-IEA-  
GO:0038128ERBB2 signaling pathway-TAS-  
GO:0042531positive regulation of tyrosine phosphorylation of STAT protein-IMP16837552  
GO:0043065positive regulation of apoptotic process-IEA-  
GO:0043066negative regulation of apoptotic process-IBA21873635  
GO:0043066negative regulation of apoptotic process-IEA-  
GO:0043410positive regulation of MAPK cascade-IBA21873635  
GO:0043653mitochondrial fragmentation involved in apoptotic process-IMP16778220  
GO:0045165cell fate commitment-IEA-  
GO:0045893positive regulation of transcription, DNA-templated-IMP15534001  
GO:0046427positive regulation of JAK-STAT cascade-IMP15534001  
GO:0046777protein autophosphorylation-IDA18334220  
GO:0046854phosphatidylinositol phosphorylation-IEA-  
GO:0051897positive regulation of protein kinase B signaling-TAS-  
GO:0060045positive regulation of cardiac muscle cell proliferation-ISS-  
GO:0060644mammary gland epithelial cell differentiation-ISS-  
GO:0060749mammary gland alveolus development-ISS-  
GO:0061026cardiac muscle tissue regeneration-ISS-  
GO:0070374positive regulation of ERK1 and ERK2 cascade-IBA21873635  
GO:0070374positive regulation of ERK1 and ERK2 cascade-IMP10348342  
GO:0071364cellular response to epidermal growth factor stimulus-IEA-  
GO:2000010positive regulation of protein localization to cell surface-IEA-  
GO:2000145regulation of cell motility-TAS-  
GO:2001223negative regulation of neuron migration-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005576extracellular region-TAS-  
GO:0005634nucleus-IDA15534001  
GO:0005654nucleoplasm-TAS-  
GO:0005737cytoplasm-IBA21873635  
GO:0005739mitochondrion-IDA16778220  
GO:0005759mitochondrial matrix-TAS-  
GO:0005829cytosol-TAS-  
GO:0005886plasma membrane-TAS-  
GO:0005887integral component of plasma membrane-IBA21873635  
GO:0009925basal plasma membrane-IBA21873635  
GO:0016021integral component of membrane-IEA-  
GO:0016323basolateral plasma membrane-IDA12646923  
GO:0043235receptor complex-IBA21873635  
GO:0043235receptor complex-IDA23382219  
KEGG ID KEGG Term
hsa04012ErbB signaling pathway
hsa04020Calcium signaling pathway
hsa04144Endocytosis
Reactome ID Reactome Term Evidence
R-HSA-1227986Signaling by ERBB2TAS
R-HSA-1227986Signaling by ERBB2IEA
R-HSA-1236394Signaling by ERBB4TAS
R-HSA-1236394Signaling by ERBB4IEA
R-HSA-1250196SHC1 events in ERBB2 signalingIEA
R-HSA-1250196SHC1 events in ERBB2 signalingTAS
R-HSA-1250342PI3K events in ERBB4 signalingTAS
R-HSA-1250347SHC1 events in ERBB4 signalingTAS
R-HSA-1251985Nuclear signaling by ERBB4TAS
R-HSA-1251985Nuclear signaling by ERBB4IEA
R-HSA-1253288Downregulation of ERBB4 signalingTAS
R-HSA-1257604PIP3 activates AKT signalingTAS
R-HSA-162582Signal TransductionTAS
R-HSA-162582Signal TransductionIEA
R-HSA-1643685DiseaseTAS
R-HSA-1963640GRB2 events in ERBB2 signalingTAS
R-HSA-1963642PI3K events in ERBB2 signalingTAS
R-HSA-199418Negative regulation of the PI3K/AKT networkTAS
R-HSA-2219528PI3K/AKT Signaling in CancerTAS
R-HSA-2219530Constitutive Signaling by Aberrant PI3K in CancerTAS
R-HSA-5663202Diseases of signal transductionTAS
R-HSA-5673001RAF/MAP kinase cascadeTAS
R-HSA-5683057MAPK family signaling cascadesTAS
R-HSA-5684996MAPK1/MAPK3 signalingTAS
R-HSA-6785631ERBB2 Regulates Cell MotilityTAS
R-HSA-6811558PI5P, PP2A and IER3 Regulate PI3K/AKT SignalingTAS
R-HSA-8847993ERBB2 Activates PTK6 SignalingTAS
R-HSA-8848021Signaling by PTK6TAS
R-HSA-8863795Downregulation of ERBB2 signalingTAS
R-HSA-8939211ESR-mediated signalingTAS
R-HSA-9006925Intracellular signaling by second messengersTAS
R-HSA-9006927Signaling by Non-Receptor Tyrosine KinasesTAS
R-HSA-9006931Signaling by Nuclear ReceptorsTAS
R-HSA-9006934Signaling by Receptor Tyrosine KinasesTAS
R-HSA-9006934Signaling by Receptor Tyrosine KinasesIEA
R-HSA-9018519Estrogen-dependent gene expressionTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
20604875ErbB receptors and fatty acid synthase expression in aggressive head and neck squamous cell carcinomas. (2010 Nov)Silva SDOral Dis
23999525Evidence from mouse and man for a role of neuregulin 3 in nicotine dependence. (2014 Jul)Turner JRMol Psychiatry
27565922Hot spot mutations in Finnish non-small cell lung cancers. (2016 Sep)Maki-Nevala SLung Cancer
24147598Molecular profiling of EGFR family in chronic obstructive pulmonary disease: correlation with airway obstruction. (2013 Dec)Anagnostis AEur J Clin Invest
15563701Expression of ErbB receptors and mucins in the airways of long term current smokers. (2004 Dec)O'Donnell RAThorax
28892072Neuregulin signaling pathway in smoking behavior. (2017 Aug 22)Gupta RTransl Psychiatry
29114105Neuregulin 3 Signaling Mediates Nicotine-Dependent Synaptic Plasticity in the Orbitofrontal Cortex and Cognition. (2018 May)Zhou LNeuropsychopharmacology
18948947Somatic mutations affect key pathways in lung adenocarcinoma. (2008 Oct 23)Ding LNature
23752247Genome-wide association study on detailed profiles of smoking behavior and nicotine dependence in a twin sample. (2014 May)Loukola AMol Psychiatry
17681096ErbB4 expression and mutation in Japanese patients with lung cancer. (2007 Jul)Sasaki HClin Lung Cancer
27784625Nicotine-induced neuroplasticity counteracts the effect of schizophrenia-linked neuregulin 1 signaling on NMDAR function in the rat hippocampus. (2017 Feb)Yamazaki YNeuropharmacology